MWI Health

MWI Health in Fargo, North Dakota offers Spravato (esketamine) for adults with treatment-resistant depression who have not found relief from traditional antidepressants. Spravato targets the NMDA receptor and raises glutamate levels, producing rapid improvement in depressive symptoms, often within hours rather than weeks.

Since January 2025, Spravato can be used on its own as a monotherapy, and it remains approved alongside oral antidepressants and for major depressive disorder with suicidal ideation. Doses are administered under supervision in the clinic, followed by at least two hours of monitoring, so patients arrange a ride home.

The Fargo location combines Spravato with MWI's broader behavioral health offerings, including psychotherapy and TMS therapy, providing a new path forward for severe, hard-to-treat depression.